Chemed (CHE) Oppenheimer 36th Annual Healthcare MedTech & Services Conference summary
Event summary combining transcript, slides, and related documents.
Oppenheimer 36th Annual Healthcare MedTech & Services Conference summary
19 Mar, 2026Guidance and outlook
Confident in VITAS guidance, with some conservatism and upward potential as patient mix balances through 2026.
Roto-Rooter guidance is conservative, set at about half the internal budgeted growth rate for revenue and EBITDA.
VITAS expects continued ADC growth, with weekly increases so far in 2026, slightly ahead of schedule.
Roto-Rooter top-line growth projected at 3%-3.5%, driven by improved water restoration collections and price increases.
Strategic alternatives for Roto-Rooter will be considered if recovery does not materialize in 2026.
VITAS segment performance
Strong volume growth in Florida, aided by favorable CON environment and new market entries; new locations are exceeding expectations and contributing significantly to organic growth.
Northeast segment has returned to growth after previous struggles; growth rates outside Florida are lower due to market differences.
Hospital admissions ratio targeted at 42%-45%, with recent trends showing a slight decrease while overall volumes rise.
Margin expansion expected as patient mix shifts to longer stays; 18%-18.5% margin projected, with gradual improvement possible through back-office leverage.
New Florida locations expected to reach profitability within 12 months, faster than historical averages.
Roto-Rooter segment performance
Water restoration write-offs expected to improve, providing a $5.5 million tailwind in 2026.
Paid lead costs remain elevated at $3 million per quarter, but marketing spend is under control and SEO efforts are showing early positive results.
Centralization of water restoration billing and collections underway, expected to improve collection rates and reduce variability.
Technology adoption (360-degree room scanning) is being tested to enhance documentation and improve insurance collections at minimal cost.
Aggressive franchisee acquisition strategy continues, with higher multiples offered and deals expected soon.
Latest events from Chemed
- VITAS drove revenue growth and guidance increases, while Roto-Rooter margins declined.CHE
Q1 202623 Apr 2026 - Proxy details director elections, auditor ratification, pay-for-performance, and strong governance.CHE
Proxy filing9 Apr 2026 - 2025 revenue up 4.1%, but margins and EPS fell; 2026 outlook is for stronger growth.CHE
Q4 20257 Apr 2026 - Proxy covers director elections, auditor ratification, say-on-pay, and strong governance practices.CHE
Proxy filing6 Apr 2026 - Sustained EPS growth, Medicare cap management, and digital innovation drive robust 2024 results.CHE
BofA Securities 2025 Healthcare Conference2 Mar 2026 - Q2 2024 featured robust VITAS growth, Roto-Rooter declines, and raised full-year guidance.CHE
Q2 20242 Feb 2026 - Expecting high single-digit revenue and 10% EPS growth, with robust M&A and expansion plans.CHE
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - VITAS growth offset Roto-Rooter softness, driving higher revenue and raised 2024 EPS guidance.CHE
Q3 202417 Jan 2026 - VITAS posts strong growth while Roto-Rooter pivots strategy amid rising competition.CHE
UBS Global Healthcare Conference 202414 Jan 2026